Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Sponsored by Keymed Biosciences Co.Ltd
About this trial
Last updated 2 years ago
Study ID
CM338-105101
Status
Recruiting
Type
Interventional
Phase
Phase 2
Placebo
No
Accepting
18 to 75 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 2 years ago
What is this trial about?
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and
safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity
of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.
What are the participation requirements?
Inclusion Criteria
- Male or female aged 18-75.
- Understand the nature of the study and sign the Informed Consent Form voluntarily.
- Take effective contraception measures throughout the study period.
Exclusion Criteria
- Used other investigational drugs within 30 days before the first study administration.
- With previous history of Human immunodeficiency virus(HIV) infection.
- Treponema pallidum antibody positive in screening period.
- May have active Mycobacterium tuberculosis infection.
- Major surgery is planned during the study.
- Other reasons the investigator believes that the subject is not suitable to participate in this study.
Locations
Location
Status
Recruiting